Sara Bonstein Sells 3,862 Shares of Advaxis, Inc. (ADXS) Stock

Advaxis, Inc. (NASDAQ:ADXS) CFO Sara Bonstein sold 3,862 shares of the company’s stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $3.30, for a total value of $12,744.60. Following the completion of the sale, the chief financial officer now owns 227,908 shares of the company’s stock, valued at approximately $752,096.40. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink.

Sara Bonstein also recently made the following trade(s):

  • On Thursday, November 2nd, Sara Bonstein sold 12,734 shares of Advaxis stock. The stock was sold at an average price of $3.19, for a total value of $40,621.46.

Advaxis, Inc. (ADXS) opened at $3.21 on Wednesday. Advaxis, Inc. has a 52-week low of $3.04 and a 52-week high of $10.88.

Advaxis (NASDAQ:ADXS) last issued its quarterly earnings results on Monday, September 11th. The biotechnology company reported ($0.80) EPS for the quarter, missing the consensus estimate of ($0.53) by ($0.27). Advaxis had a negative net margin of 655.66% and a negative return on equity of 93.54%. The company had revenue of $3.05 million for the quarter, compared to analyst estimates of $3.43 million. research analysts expect that Advaxis, Inc. will post -2.21 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This article was first published by Transcript Daily and is the property of of Transcript Daily. If you are accessing this article on another publication, it was illegally stolen and republished in violation of US and international trademark and copyright legislation. The original version of this article can be viewed at https://transcriptdaily.com/2017/11/08/sara-bonstein-sells-3862-shares-of-advaxis-inc-adxs-stock.html.

Hedge funds and other institutional investors have recently modified their holdings of the stock. Voya Investment Management LLC boosted its position in Advaxis by 20.3% during the second quarter. Voya Investment Management LLC now owns 17,612 shares of the biotechnology company’s stock valued at $114,000 after purchasing an additional 2,975 shares during the last quarter. Cutler Capital Management LLC acquired a new position in Advaxis during the second quarter valued at approximately $130,000. Northern Capital Management LLC boosted its position in Advaxis by 14.6% during the second quarter. Northern Capital Management LLC now owns 20,775 shares of the biotechnology company’s stock valued at $135,000 after purchasing an additional 2,650 shares during the last quarter. Stonebridge Capital Management Inc. acquired a new position in Advaxis during the second quarter valued at approximately $146,000. Finally, PNC Financial Services Group Inc. boosted its position in Advaxis by 18.2% during the second quarter. PNC Financial Services Group Inc. now owns 26,000 shares of the biotechnology company’s stock valued at $168,000 after purchasing an additional 4,000 shares during the last quarter. 48.00% of the stock is owned by hedge funds and other institutional investors.

Several brokerages have issued reports on ADXS. BidaskClub upgraded Advaxis from a “hold” rating to a “buy” rating in a report on Saturday, September 9th. ValuEngine upgraded Advaxis from a “strong sell” rating to a “sell” rating in a report on Friday, September 8th. HC Wainwright restated a “buy” rating and issued a $23.00 price target on shares of Advaxis in a report on Friday, September 15th. Finally, Cantor Fitzgerald restated a “buy” rating and issued a $19.00 price target on shares of Advaxis in a report on Monday, September 25th.

About Advaxis

Advaxis, Inc is a clinical-stage biotechnology company focused on the discovery, development and commercialization of Listeria monocytogenes (Lm)-Listeriolysin O (LLO) cancer immunotherapies. These immunotherapies are based on a platform technology that utilizes live attenuated Lm bioengineered to secrete antigen/adjuvant fusion proteins.

Insider Buying and Selling by Quarter for Advaxis (NASDAQ:ADXS)

Receive News & Ratings for Advaxis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Advaxis Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply